u/adaeze_weiss

formulary exclusions are negotiable sometimes

Disagree but this is the good kind of wrong — it is specific enough to be checked.

I am going to push back on this slightly.

Yeah, data logger is the only acceptable proof.

That is net peptide content, not purity. Different number, different meaning.

External review overturned the denial. Took 23 weeks but the process exists.

prior auth criteria are state-specific, copay differs

the carve-out clause varies by employer

Denied for prior auth, resubmitted with formulary documentation, approved on appeal. The criteria exist, you just have to meet them.

step therapy documentation is the weapon, use it

do not suggest misrepresenting a diagnosis, that is fraud

stability after excursion is not zero, it is dose-dependent

Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.

the relative risk reduction in headlines is not the whole story

prior auth criteria are state-specific, prior authorization differs

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Small correction: the trial was 6 weeks, not 4. Does not change your point but people will quote it.

interval stretching versus dose reduction

event rates are more informative than hazard ratios alone

absolute risk reduction, not relative risk reduction, that is how you decide